Article Text

PDF
Short report
Physical compatibility of pentoxifylline and intravenous medications
  1. S M D K Ganga Senarathna1,
  2. Tobias Strunk2,3,
  3. Michael Petrovski4,
  4. Kevin T Batty1
  1. 1School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Western Australia, Australia
  2. 2Neonatal Directorate, King Edward Memorial Hospital for Women, Perth, Western Australia, Australia
  3. 3UWA Centre for Neonatal Research and Education, School of Medicine, University of Western Australia, Perth, Western Australia, Australia
  4. 4Pharmacy Department, King Edward Memorial Hospital for Women, Perth, Western Australia, Australia
  1. Correspondence to Dr Kevin T Batty, School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA U1987, Australia; kevin.batty{at}curtin.edu.au

Abstract

Objective To investigate the physical and chemical compatibility of pentoxifylline (PTX) with a wide range of parenteral medications used in the neonatal intensive care setting.

Design PTX and drug solutions were combined in glass phials and inspected visually for physical incompatibility. The chemical compatibility was evaluated on the basis of PTX concentrations.

Results Precipitation, colour change or turbidity was not visible in any of the test mixtures, indicating no observed physical incompatibility or apparent risk of blockage in narrow-bore intravenous tubing. The PTX concentration was approximately 2.5% and 4.5% lower when combined with dopamine and amoxicillin, respectively. The PTX concentration ratios for all other combinations were in the range of 99%–102%.

Conclusion In simulated Y-site conditions, physical compatibility testing of PTX and 30 parenteral medications revealed no evidence of precipitation. Based on PTX concentration tests, it could be prudent to avoid mixing PTX with dopamine or amoxicillin.

  • intravenous drugs
  • neonates
  • pentoxifylline
  • pharmaceutical compatibility

Statistics from Altmetric.com

Footnotes

  • Contributors TS, MP, KTB and SMDKGS conceived and designed the study. SMDKGS had principal responsibility for acquiring the data and was supported by KTB. KTB conducted initial analysis and interpretation of the data, with advice from TS, MP and SMDKGS. KTB and SMDKGS prepared the first draft of the manuscript; revision and additional contributions to the manuscript were provided by TS and MP. All authors approved the final manuscript.

  • Funding This work was supported by Telethon Channel 7 Women’s and Infants’ Research Foundation (TS), the Department of Pharmacy at King Edward Memorial Hospital for Women and the Faculty of Health Sciences, Curtin University.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.